CCM
PACB icon

Catapult Capital Management’s Pacific Biosciences PACB Stock Holding History

Catapult Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-50,000
Closed -$276K – 232
2013
Q3 		$276K Buy
+50,000
New +$174K 0.03% 228

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catapult Capital Management's PACB Position: Q4 2013 in Review

Catapult Capital Management sold out of Pacific Biosciences (PACB) in Q4 2013, closing a stake of 50,000 shares — an estimated $276K sold.

Catapult Capital Management first reported a position in PACB in Q3 2013 and held it in 1 quarter. The position peaked at $276K in Q3 2013. 80 funds tracked by Wall St. Rank hold PACB as of Q4 2013.

  • Catapult Capital Management reported no remaining Pacific Biosciences position as of Q4 2013 after selling out during the quarter.
  • Catapult Capital Management sold 50,000 Pacific Biosciences shares in Q4 2013, an estimated $276K.
  • Catapult Capital Management first reported a position in Pacific Biosciences in Q3 2013 and held it in 1 quarter.
  • Catapult Capital Management's Pacific Biosciences position peaked at $276K in Q3 2013.
  • 80 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2013.

Based on Catapult Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.